Short Interest in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Drops By 16.0%

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 3,620,000 shares, a drop of 16.0% from the December 15th total of 4,310,000 shares. Based on an average daily trading volume, of 3,270,000 shares, the short-interest ratio is currently 1.1 days.

Analyst Ratings Changes

MRNS has been the topic of a number of research reports. Truist Financial cut Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target on the stock in a report on Monday, September 23rd. JMP Securities reaffirmed a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Finally, EF Hutton Acquisition Co. I upgraded shares of Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ MRNS traded down $0.00 during mid-day trading on Friday, hitting $0.54. The company’s stock had a trading volume of 1,393,785 shares, compared to its average volume of 2,936,145. The company’s fifty day simple moving average is $0.37 and its 200-day simple moving average is $0.99. Marinus Pharmaceuticals has a one year low of $0.22 and a one year high of $10.50. The stock has a market cap of $29.81 million, a price-to-earnings ratio of -0.22 and a beta of 1.03.

Institutional Investors Weigh In On Marinus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC boosted its position in shares of Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 12,934 shares in the last quarter. Point72 DIFC Ltd bought a new position in Marinus Pharmaceuticals during the second quarter worth about $28,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Marinus Pharmaceuticals in the second quarter valued at about $64,000. World Investment Advisors LLC bought a new stake in shares of Marinus Pharmaceuticals in the third quarter worth about $104,000. Finally, Jacobs Levy Equity Management Inc. raised its position in shares of Marinus Pharmaceuticals by 39.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after purchasing an additional 117,255 shares during the period. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.